Related Experiment Videos
alpha Interferon in the management of essential thrombocythaemia
M Giralt1, D Rubio, M T Cortés
1Department of Hematology, Hospital Miguel Servet, Zaragoza, Spain.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1991
Summary
Interferon alfa-2b effectively treated essential thrombocythaemia, but dose reduction was needed due to side effects. Low-dose interferon alfa-2b is recommended for symptomatic patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Essential thrombocythaemia is a myeloproliferative neoplasm characterized by elevated platelet counts.
- Interferon alfa-2b has been explored as a treatment for essential thrombocythaemia.
- Understanding treatment efficacy and toxicity is crucial for patient management.
Purpose of the Study:
- To evaluate the efficacy and safety of interferon alfa-2b in treating essential thrombocythaemia.
- To determine optimal dosing and maintenance strategies for interferon alfa-2b therapy.
Main Methods:
- Thirteen patients with essential thrombocythaemia received subcutaneous interferon alfa-2b (3 MU/day) for 12 weeks.
- Dose reduction was implemented after 4 weeks for all patients.
- Response criteria included platelet count normalization and assessment of clinical symptoms.
Main Results:
- Nine patients (69.2%) achieved objective responses, with two (15.4%) achieving complete response.
- All patients required a dose reduction due to acute (flu-like symptoms) and chronic (leukopenia) toxicities.
- Maintenance therapy with a reduced dose (5 MU twice weekly) was effective in sustained responses.
Conclusions:
- Interferon alfa-2b shows efficacy in essential thrombocythaemia but necessitates dose adjustments due to frequent side effects.
- Low-dose interferon alfa-2b is advisable, targeting patients with significant symptoms of thrombocytosis.
- Careful monitoring for toxicity is essential during interferon alfa-2b treatment.